PUBLICAÇÕES científicas

/cun/pt/investigacion/publicaciones-cientificas/areaMain/02
  • Cancer-Associated Thrombosis: Beyond Clinical Practice Guidelines-A Multidisciplinary (SEMI-SEOM-SETH) Expert Consensus

    Pachón V (1), Trujillo-Santos J (2), Domènech P (3), Gallardo E (4), Font C (5), González-Porras JR (6), Pérez-Segura P (7), Maestre A (8), Mateo J (9), Muñoz A (10), Peris ML (11), Lecumberri R (12).

    (1) Department of Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
    (2) Department of Internal Medicine, Hospital Universitario Santa Lucía, Cartagena, Spain.
    (3) Thrombosis and Haemostasis Unit, Hospital Universitario Bellvitge, L'Hospitalet de Llobregat, Catalonia, Spain.
    (4) Department of Oncology, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Sabadell, Spain.
    (5) Department of Medical Oncology, Hospital Clinic, Barcelona, Spain.
    (6) Hematology Service, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain.
    (7) Department of Oncology, Hospital Clínico San Carlos, Madrid, Spain.
    (8) Department of Internal Medicine, Hospital del Vinalopó, Elche, Spain.
    (9) Hematology Service, Hospital Santa Creu i Sant Pau, Barcelona, Spain.
    (10) Department of Oncology, Hospital Universitario Gregorio Marañón, Madrid, Spain.
    (11) Department of Internal Medicine, Hospital Provincial de Castellón, Castellón, Spain.
    (12) Hematology Service, Clínica Universidad de Navarra, IDISNA, CIBER-CV, Pamplona, Spain.

    TH Open 05 de NOVEMBRO de 2019

  • Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

    Antonio González-Martín, M.D., Ph.D., Bhavana Pothuri, M.D., Ignace Vergote, M.D., Ph.D., René DePont Christensen, Ph.D., Whitney Graybill, M.D., Mansoor R. Mirza, M.D., Colleen McCormick, M.D., M.P.H., Domenica Lorusso, M.D., Ph.D., Paul Hoskins, M.D., Gilles Freyer, M.D., Klaus Baumann, M.D., Kris Jardon, M.D., et al., for the PRIMA/ENGOT-OV26/GOG-3012 Investigators*

    From Grupo Español de Investigación en Cáncer de Ovario (GEICO) and the Medical Oncology Department, Clínica Universidad de Navarra (A.G.-M.) and GEICO and Hospital Universitario La Paz-IdiPAZ (A.R.), Madrid, GEICO and Medical Oncology, Catalan Institute of Oncology, Girona Biomedical Research Institute, and the Department of Medical Sciences, Medical School University of Girona, Girona (P.B.-G.), and GEICO and Hospital Universitario Reina Sofía, Cordoba (M.J.R.-P.) - all in Spain; the Gynecologic Oncology Group (GOG) and the Department of Obstetrics/Gynecology, Perlmutter Cancer Center, NYU Langone Health (B.P.), and GOG and the Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College (R.E.O.), New York, and US Oncology Research (USOR) and the Division of Gynecologic Oncology, Wilmot Cancer Institute, Department of Obstetrics and Gynecology, University of Rochester, Rochester (R.G.M.) - all in New York; Belgium and Luxembourg Gynecologic Oncology Group (BGOG) and the Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven (I.V.), BGOG and the Department of Medical Oncology and Hematology, AZ Maria Middelares, Ghent (C.V.), and the Department of Molecular Imaging, Pathology, Radiotherapy, and Oncology, Center for Oncological Research, Antwerp University, Antwerp (C.V.) - all in Belgium; the Nordic Society of Gynecologic Oncology (NSGO) and the Research Unit of General Practice, Institute of Public Health, University of Southern Denmark, Odense (R.D.C.), NSGO and Rigshospitalet-Copenhagen University Hospital, Copenhagen (M.R.M.), and NSGO and the Department of Oncology, Aalborg University, Aalborg (B.L.) - all in Denmark; GOG and Gynecologic Oncology, Medical University of South Carolina, Charleston (W.G.); GOG and Legacy Medical Group Gynecologic Oncology, Portland, OR (C.M.); Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO) and Fondazione IRCCS National Cancer Institute of Milan (D.L.), and MITO and the Department of Obstetrics and Gynecology, San Raffaele Scientific Institute (G.M.) - both in Milan; USOR and the Department of Medical Oncology, BC Cancer, Vancouver, BC (P.H.), and GOG and the Department of Obstetrics and Gynecology, McGill University, and the Department of Oncology, McGill University Health Centre, Division of Gynecologic Oncology, Montreal (K.J.) - all in Canada; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens and Service d'Oncologie Médicale, Centre Hospitalier Lyon-Sud, Lyon, France (G.F.); Arbeitsgemeinschaft Gynäkologische Onkologie and the Department of Gynecology and Obstetrics, Klinikum der Stadt Ludwigshafen, Ludwigshafen, Germany (K.B.); the Division of Gynecologic Oncology, Ohio State University, Columbus (F.B.); GOG and the Division of Gynecologic Oncology, University of Pennsylvania, Philadelphia (A.F.H.), and GOG and Hanjani Institute for Gynecologic Oncology, Asplundh Cancer Pavilion, Abington Jefferson Hospital, Sidney Kimmel Medical College of Thomas Jefferson University, Willow Grove (M.S.S.) - all in Pennsylvania; GOG and the Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee (W.H.B.); Israeli Society of Gynecologic Oncology and Department of Gynecology and Gynecologic Oncology, Hillel Yaffe Medical Center, Technion Israel Institute of Technology, Haifa, Israel (I.B.); GlaxoSmithKline/Tesaro, Waltham, MA (K.S., I.A.M., Y.L., D.G.); and Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix (B.J.M.).

    The New England Journal of Medicine 28 de SETEMBRO de 2019

  • Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma

    Wang M (1), Rule S (2), Zinzani PL (3), Goy A (4), Casasnovas O (5), Smith SD (6), Damaj G (7), Doorduijn JK (8), Lamy T (9), Morschhauser F (10), Panizo C (11), Shah B (12), Davies A (13), Eek R (14), Dupuis J (15), Jacobsen E 16, Kater AP (17), Le Gouill S (18), Oberic L (19), Robak T (20), Jain P (21), Frigault MM (22), Izumi R (22), Nguyen D (22), Patel P (22), Yin M (22), Długosz-Danecka M (2)3.

    (1) MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
    (2) Plymouth University Medical School, Plymouth, UK.
    (3) Institute of Hematology "Seràgnoli", University of Bologna, Bologna, Italy.
    (4) John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.
    (5) CHU Dijon - Hôpital d'Enfants, Dijon, France.
    (6) Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.
    (7) Institut d'Hématologie de Basse-Normandie, Caen, France.
    (8) Erasmus MC, HOVON Lunenburg Lymphoma Phase I/II Consortium, Rotterdam, Netherlands.
    (9) CHU de Rennes, Rennes, France.
    (10) Univ. Lille, CHU Lille, EA 7365-GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, F-59000, Lille, France.
    (11) Clínica Universidad de Navarra, Pamplona, Spain.
    (1)2 Moffitt Cancer Center, Tampa, FL, USA.
    (13) Cancer Research UK Centre, University of Southampton Faculty of Medicine, Southampton, UK.
    (14) Border Medical Oncology, Albury, Victoria, Australia.
    (15) Unité Hémopathies Lymphoïdes, AP-HP Hôpital Henri Mondor, Créteil, France.
    (16) Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
    (17) Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, HOVON Lunenburg Lymphoma Phase I/II Consortium, Amsterdam, Netherlands.
    (18) CHU de Nantes-Hotel Dieu, Nantes, France.
    (19) Institut Universitaire du Cancer-Oncopole Toulouse (IUCT-O), Toulouse, France.
    (20) Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland.
    (21) MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
    (22) Acerta Pharma, South San Francisco, CA, USA.
    (23) Department of Haematology, Jagiellonian University, Krakow, Poland.

    Leukemia 26 de SETEMBRO de 2019

  • NLRP3 inflammasome blockade reduces adipose tissue inflammation and extracellular matrix remodeling

    Unamuno X (1,2), Gómez-Ambrosi J (1,2,3), Ramírez B (1,2,3), Rodríguez A (1,2,3), Becerril S (1,2,3), Valentí V (2,3,4), Moncada R (2,3,5), Silva C (2,6), Salvador J (2,6), Frühbeck G (7,8,9,10), Catalán V (11,12,13).

    (1) Metabolic Research Laboratory, Clínica Universidad de Navarra, Pamplona, Spain.
    (2) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Pamplona, Spain.
    (3) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
    (4) Department of Surgery, Clínica Universidad de Navarra, Pamplona, Spain.
    (5) Department of Anesthesia, Clínica Universidad de Navarra, Pamplona, Spain.
    (6) Department of Endocrinology & Nutrition, Clínica Universidad de Navarra, Pamplona, Spain.
    (7) Metabolic Research Laboratory, Clínica Universidad de Navarra, Pamplona, Spain.
    (8) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Pamplona, Spain.
    (9) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
    (10) Department of Endocrinology & Nutrition, Clínica Universidad de Navarra, Pamplona, Spain.
    (11) Metabolic Research Laboratory, Clínica Universidad de Navarra, Pamplona, Spain.
    (12) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Pamplona, Spain.
    (13) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.

    Cellular Molecular Immunology 24 de SETEMBRO de 2019

  • Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation

    Caballero-Velázquez T (1), Calderón-Cabrera C (1), López-Corral L (2), Puig N (2), Marquez-Malaver F (1), Pérez-López E (2), García-Calderón C (1), Rosso-Fernández CM (1), Caballero Barrigón D (2), Martín J (1), Mateos MV (2), San Miguel J (3), Pérez-Simón JA (4); European Myeloma Network.

    (1) Department of Hematology, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC/CIBERONC), Universidad de Sevilla, Seville, Spain.
    (2) Department of Hematology, Complejo Asistencial Universitario de Salamanca-IBSAL-CIBERONC, Centro de Investigación del Cáncer-IBMCC, Salamanca, Spain.
    (3) Clínica Universidad de Navarra, Centro Investigación Médica Aplicada (CIMA), IDISNA, CIBERONC, Pamplona, Spain.
    (4) Department of Hematology, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC/CIBERONC), Universidad de Sevilla, Seville, Spain.

    Bone Marrow Transplantation 24 de SETEMBRO de 2019

talvezlhe interesse

QUE TECNOLOGIA UTILIZAMOS? 

A Clínica é o hospital privado com maiores recursos tecnológicos de Espanha, tudo num único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OS NOSSOS
PROFISSIONAIS

Os profissionais da Clínica realizam um trabalho contínuo de investigação e formação, sempre em benefício do paciente.

Imagen profesionales de la Clínica Universidad de Navarra

RAZÕES PARA VIR
À CLÍNICA

Conheça porque é que somos diferentes em relação a outros centros sanitários. Qualidade, rapidez, comodidade e resultados.

Imagen del edificio de la Clínica Universidad de Navarra